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Multiple myeloma (MM) 4 is the second most common hematologic malignancy with over 30,000 new cases diagnosed annually in the United States. Currently, MM is generally considered an incurable disease with a median survival of 5-7 years from diagnosis (1) . MM is characterized by the uncontrolled proliferation and accumulation of antibody-secreting plasma cells primarily in the bone marrow (1) . It is a complex disease with respect to clinical features, cytogenetic abnormalities, and cellular and molecular factors that contribute to disease development and progression (1) (2) (3) (4) . High throughput whole-genome and whole-exome sequencing efforts have identified frequent MM cell-intrinsic genetic alterations in the components of several signaling pathways, including RAS/MEK/MAPK, JAK2/STAT3, and nuclear factor-B (NF-B) (5) (6) (7) (8) . In addition to cell-intrinsic changes, the tumor microenvironment (TME) further provides cancer cell-extrinsic influences on MMcells,promotinggrowth,survival,migration,anddrugresistance (9) . For example, bone marrow stromal cells (BMSCs) can secrete cytokines, growth factors, and additional factors to create a niche for MM cells to thrive by promoting local expansion, immune evasion, and metastasis (4, 10 -12) .
Proteasome inhibition by bortezomib/Velcade has been a key strategy in the treatment of both newly diagnosed and relapsed MM. Bortezomib is believed to suppress multiple signaling pathways, including stabilization of cell cycle-inhibitory proteins p21 and p27 (13) , tumor-suppressor protein p53 (14) , and the inhibitor of NF-B, IB␣ (15) . In addition, bortezomib is known to induce the unfolded protein response, which monitors endoplasmic reticulum stress to maintain quality control of proteins and homeostasis (16) . MM cells are highly susceptible to proteasome inhibition in vivo, possibly arising from the excessive demand of the endoplasmic reticulum system to maintain the high secretion load of immunoglobulins (17) (18) (19) . Although the widespread use of proteasome inhibitors has improved response and survival, the majority of MM patients eventually develop refractory disease (1) (2) (3) (4) . Multiple distinct mechanisms of bortezomib resistance have been described, including point mutations of the 26S PSMB5 (proteasome subunit ␤ type 5), decreased expression of unfolded protein response proteins, and changes in critical pathways, such as ␤-catenin, insulin growth factor receptor, MAPK, AKT, KRAS, and JAK/STAT (5, 6, 8, 20, 21) . Activation of NF-B has also been implicated in bortezomib resistance (22, 23) .
NF-B is a family of transcription factors that has emerged as a critical pathogenic factor in MM development and drug resistance (24 -27) . Normally, NF-B (p50-RelA or cRel complexes) is sequestered in the cytoplasm by its inhibitor proteins, including IB␣ and IB␤. "Canonical" activation of NF-B requires the engagement of the IB kinase complex composed of IKK␣, IKK␤, and IKK␥/NEMO. The IKK complex then causes sitespecific phosphorylation of IB proteins to cause degradation by the ubiquitin-26S proteasome pathway (28, 29) . Alternatively, the "noncanonical" NF-B activation pathway involves the action of NF-B-inducing kinase and IKK␣ and limited processing of NFB2/p100 to p52 by the 26S proteasome to selectively activate p52-RelB complex (30) . Accumulated data, including the analysis of gene expression signatures (31) and NF-B-RelA immunostaining (32) , have shown that NF-B signaling is constitutively active in MM cells of ϳ90% of patients. Although MM cancer cell genome and exome sequencing has identified genetic aberrations in canonical and noncanonical NF-B signaling components in up to ϳ23% of MM cases (5, 6, 8, 31, 33) , the mechanisms of NF-B activation in the remaining 70% of MM cases remain unclear. Such an activation could be dependent on extrinsic factors, such as those derived from the TME.
We previously reported that the constitutive NF-B activity present in freshly isolated patient-derived MM cells is often resistant to inhibition by bortezomib in vitro (34) , and such a bortezomib-resistant NF-B activity could be further induced in MM cells via a factor that is secreted by BMSCs obtained directly from MM patients (35) . This bortezomib-resistant NF-B activity seems to embody an atypical NF-B pathway, termed proteasome inhibitor-resistant (PIR), which involves IB␣ degradation and NF-B activation that are highly resistant to inhibition by a variety of proteasome inhibitors, including bortezomib (36 -38) . Paradoxically, bortezomib has also been shown to cause NF-B activation while blocking the proteasome activity (34, 39) , unlike NF-B activity in MM cells that had often been attributed to bortezomib-sensitive pathways (26, 27) .
In this current study, we identified a BMSC-secreted factor, hyaluronan and proteoglycan link protein 1 (HAPLN1), that can induce bortezomib-resistant NF-B activity in MM cells. Specifically, HAPLN1 proteoglycan tandem repeat (PTR) domain 1 and 2 fragments have strong PIR NF-B-inducing activities. This was surprising, because HAPLN1 is an extracellular matrix (ECM) protein well-known for its role in structural support in cartilage formation and other tissue ECM (40, 41) , but with no previously characterized direct signaling functions through the PTR domains. Importantly, HAPLN1 PTR fragments confer bortezomib-resistant survival in some MM cells and are frequently detectable in MM patient bone marrow aspirates. Our study reveals a novel inducer of drug-resistant NF-B activity in MM, which could represent a novel therapeutic target for this currently incurable disease.
Results

HAPLN1 PTR domains activate NF-B in myeloma cells
We previously demonstrated that MM patient-derived BMSCs can cause bortezomib-resistant NF-B activity in MM cells through a secreted soluble factor (35) . Partial purification of this factor from a stromal cell line was described previously (35) . Following SDS-PAGE, Coomassie Blue staining, and mass spectrometry analysis of the enriched fraction F3 (Fig. 1A) , we identified four potential factors: calumenin, osteonectin, galectin-3-binding protein, and HAPLN1. cDNAs encoding these proteins were isolated from MM patient BMSCs, cloned into a pSecTag2a vector for efficient secretion, sequence-verified, and transiently transfected into HEK293 cells. Conditioned media (CMs) from transfected HEK293 cells were applied to a MM cell line, RPMI8226, to assay for NF-B activation by an electrophoretic mobility shift assay (EMSA), whereas the presence of corresponding proteins was verified by immunoblot analysis of the CM (Fig. 1, B-E) . Only the HAPLN1-containing CM induced NF-B activation (Fig. 1E ). Importantly, this NF-B activation was highly resistant to bortezomib treatment ( Fig. 1E ).
HAPLN1 is a 45-52-kDa ECM protein containing a signal peptide (SP), one immunoglobulin-like (IG), and two PTR domains (PTR1 and PTR2) ( Fig. 2A) (42, 43) . We found that full-length human HAPLN1 (FL-H1) ( Fig. 2B ) was unable to induce NF-B activation in MM cells ( Fig. 2C ). ECM proteins can sometimes generate smaller active signaling factors, matrikines, via proteolysis (44) . We observed smaller species of HAPLN1 in HEK293 CM (Fig. 1D ); therefore, we tested whether subdomains of HAPLN1 were sufficient to cause NF-B activation. We expressed HAPLN1 subdomains as GSTfused recombinant fragments in Escherichia coli and purified them by GSH-Sepharose chromatography (Fig. 2B ). We found that the HAPLN1 PTR1 (H1-P1) and PTR2 (H1-P2) domains activated NF-B ϳ6.6-fold and ϳ6.8-fold, respectively (Fig.  2C ). The IG domain (H1-IG) caused NF-B activation but to a much lesser degree than that induced by H1-P1 ( Fig. 2C ) and therefore was not further pursued here. To rule out the possibility that NF-B activation was due to the presence of contaminating endotoxin, we measured the amounts of endotoxin in H1-P1 preparations. The levels of contaminating endotoxin were found to be Ͻ0.2 ng/ml, below the sensitivity of the NF-B activation assay in RPMI8226 cells (Fig. 2 , D and E).
We further characterized NF-B activation in MM cells using H1-P1 domain due to its strong NF-B activation potential coupled with robust expression and purification relative to other HAPLN1 forms. Additionally, known glycosylation sites lie within the N-terminal region of HAPLN1 far upstream of the PTR domains; therefore, H1-P1-mediated NF-B activation
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does not involve glycosylation (45) . Dose-response and time course analyses demonstrated that NF-B activity is induced by as low as 10 nM H1-P1 and saturates at 100 nM ( Fig. 3A ). Activation occurs within 1 h, peaks at 2-4 h, and persists through 24 h of treatment ( Fig. 3B ). Supershift analysis using antibodies selective for NF-B family members demonstrated that p50 and p65 (RelA) are activated within 2 h ( Fig. 3C ). H1-P1c, which contains no GST tag, was also capable of inducing NF-B activity ( Fig. 3 , D and E). However, due to generally poor solubility of the cleaved H1-P1 domain, we employed GST-tagged H1-P1 in the remainder of the study. HAPLN1 is known to be cleaved between residues 31 and 32 by multiple metalloproteinases, including MMP9 (gelatinase B) (46) , and removal of the N-terminal 31 amino acids to create HAPLN1(32-354) was also able to cause NF-B activation ( Fig. 3F ).
H1-P1-induced NF-B activation was not limited to the RPMI8226 MM cell line, as stimulation of additional myeloma cell lines, such as MM.1S and H929, also showed NF-B activation ( Fig. 3G ). EMSA analysis of different cell types stimulated with H1-P1 indicated that H1-P1-mediated NF-B activity is not limited to MM cell lines but can also be seen in some lymphoma (e.g. mantle cell lymphoma) and leukemia cell lines to varying degrees (summarized in Table 1 ). Thus, these studies demonstrate that HAPLN1 and its PTR domains possess a previously unprecedented NF-B signaling potential in MM cell and certain other cancer cell types.
HAPLN1-PTR1-induced NF-B activation does not involve hyaluronic acid binding
HAPLN1 links hyaluronic acid (HA) to specific proteoglycans, such as versican (42, 43) . Currently, HA binding is the only known biochemical function of the PTR domains. Thus, it is possible that H1-P1 binds HA to signal through cell surface receptors, such as RHAMM, CD44, and TLR-2/4 to induce NF-B signaling (4, 47, 48) . To test the possible role of HA binding in HAPLN1-mediated signaling, we added low-or high-molecular weight HA forms, alone or in conjunction with H1-P1, but these did not alter NF-B activation (Fig. 4, A and  B) . Moreover, treatment with hyaluronidase did not affect H1-P1-induced NF-B activation (Fig. 4B ). Blundell et al. (49) determined critical residues for HA binding in the PTR domain of a H1-P1-related protein, TSG-6. We mutated the 6 conserved residues in H1-P1 to alanines (H1-P1 HABD mt), but these did not affect NF-B activation in MM cells ( Fig. 4C ). Taken together, these data suggest that HAPLN1-PTR1 causes NF-B activation in MM cells in a manner independent of HA binding.
HAPLN1-PTR1 causes bortezomib-resistant IB␣ degradation
Whereas canonical and noncanonical activation pathways of NF-B depend on the proteasome activity, we identified HAPLN1 as a factor capable of inducing bortezomib-resistant NF-B activity (Fig. 1E ). Thus, we next compared the bort- ezomib dose response for inhibition of NF-B activity with a proteasome activity assay (Proteasome Glo) ( Fig. 5 , A-C). Bortezomib showed maximal inhibition of both TNF␣-induced NF-B activity and proteasome activity at 10 nM bortezomib ( Fig. 5 , B and C). In contrast, H1-P1-induced NF-B activation was significantly more resistant to bortezomib at doses of 10 -100 nM (Fig. 5, A and B) . H1-P1 did not affect the ability of bortezomib to block proteasome activity at these doses ( Fig.  5C) ; thus, the lack of NF-B inhibition was not due to reduced bortezomib efficacy or increased proteasome activity. NF-B activation by H1-P1 was also resistant to lactacystin, another proteasome inhibitor, unlike TNF␣ ( Fig. 5D ). Increasing concentrations of TNF␣ did not limit the bortezomib-mediated inhibition of NF-B ( Fig. 5E ), indicating that bortezomib is capable of fully inhibiting canonical NF-B activation, no matter what the dose of TNF␣ used.
The above observations suggest an atypical mechanism at play in H1-P1-induced NF-B activation. This activation occurs in the presence of cycloheximide (see below), thus indicating that new protein synthesis is not required for activation. Stimulation with H1-P1 caused degradation of IB␣ protein from 1 to 3 h, which was highly resistant to treatment with 100 nM bortezomib (Fig. 6, A and B) . Bortezomib alone does not affect IB␣ degradation. Canonical NF-B activation induced by TNF␣ is accompanied by the accumulation of phosphorylated and ubiquitinated intermediates of IB␣ preceding degradation by the proteasome; however, H1-P1-induced IB␣ degradation was not readily accompanied by the IB␣ intermediates preceding degradation by the proteasome (Fig. 6C ). EMSA analysis indicated that bortezomib caused ϳ40% inhibition of NF-B activation induced by H1-P1 ( Fig. 5B) ; however, IB␣ continued to be degraded in the presence of bortezomib ( Fig. 6,  A-B ). This suggests that another IB family member could be involved in this inhibition. Indeed, H1-P1 caused degradation of IB␤, but IB␤ degradation was more susceptible to inhibition by bortezomib than IB␣ degradation (Fig. 6, A and B) . Interestingly, IKK16, an IB kinase (IKK) inhibitor, and MLN4924, a NEDD8-activating enzyme inhibitor that is critical for activation of SCF-type ubiquitin ligases, such as ␤-TrCP required for IB␣ ubiquitination (50, 51) , could inhibit H1-P1mediated NF-B activation and IB␣ degradation ( Fig. 6 , D-F). H1-P1-induced phospho-IB␣ species became readily detectable in the presence of MLN4924 (Fig. 6 , E and F). Collectively, these results indicate that HAPLN1-PTR1 causes degradation of both IB␣ and IB␤, but IB␣ degradation is resistant to bortezomib, thus explaining significant resistance of H1-P1- 
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induced NF-B activation to proteasome inhibition in MM cells. However, both IKK and NEDD8-activating enzyme inhibitors blocked IB␣ degradation and NF-B activation induced by H1-P1, suggesting that this activation also involves components of the canonical NF-B-signaling pathway.
HAPLN1 is detectable in myeloma patient BMSCs and BM plasma
We previously showed that BMSC-induced NF-B activity was highly variable from patient to patient (35) . To test whether production of HAPLN1 by myeloma patient-derived bone marrow stromal cells (MM-BMSCs) is also highly variable, we utilized qRT-PCR primers that can detect a common region of six of seven splice variants (ENSEMBL database; the shortest variant contains only the IG domain) to measure the expression of HAPLN1 mRNAs in MM patient-derived BMSCs. HAPLN1 mRNA was observed in different MM-BMSCs at highly variable levels (0.3-180 relative expression) ( Fig. 7A ).
Numerous ECM proteins can undergo proteolysis to release biologically active signaling fragments, called matrikines (44, (52) (53) (54) . We found that FL-H1 was unable to induce NF-B activation in MM cells (Fig. 2, C and D) , but PTR1 and -2 induced NF-B activation (Fig. 2, C and D) . Because HAPLN1 is known to be proteolyzed and multiple subdomains have NF-B-inducing capabilities, we characterized several HAPLN1 antibodies (Fig. 7 , B and C) to determine HAPLN1 expression in BMSC CM. Two antibodies, H-93 and HPA019482 (HPA), that react with the IG domain ( Fig. 7 , B and C), detected immunoreactivities at ϳ40 kDa in four of seven BMSC samples analyzed ( Fig. 7D ), whereas two additional antibodies that detect PTR1 and PTR2 domains (K-14 and C-14, respectively) did not detect any other species in BMSC CMs (not shown). There was no correlation between HAPLN1 RNA expression and protein detection in CMs, although secretion-positive BMSCs tended to be above the mean RNA expression ( Fig. 7A) . 
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We next analyzed HAPLN1 species in BM plasma from aspirates of relapsed/refractory MM patients ( Table 2 ). All four antibodies employed detected immunoreactivities at ϳ40 -44 kDa in 3 of 15 patient samples analyzed (patients 5, 9, and 15) ( Fig. 7E ). K-14 and C-14, which detect PTR1 and PTR2 domains, respectively, also detected smaller fragments of 20 -25 kDa in 9 of 15 patient BM plasma samples (patients 4, 5, 8 -10, and 12-15) ( Fig. 7E ). This suggests that these smaller species in patient BM samples are HAPLN1 fragments containing the PTR1/2 domains but not the IG domain. Of note, of the 15 patients analyzed for BM plasma, five had progressive disease at the time of biopsy; HAPLN1 was detectable in four of them (patients 10 and 13-15). The detection of HAPLN1 in patients with progressive disease versus others was statistically significantly different (p ϭ 0.04, Wilcox-Mann-Whitney, twotailed). Overall, our results indicate that HAPLN1 is (i) variably produced by BMSCs, (ii) present in patient BM plasma in both larger forms (ϳ40 -44 kDa) containing all three domains and smaller forms (20 -25 kDa) containing PTR1/2 domains but lacking the IG domain, and (iii) potentially associated with progressive disease.
HAPLN1-PTR1 causes bortezomib resistance in myeloma cells
We previously showed that BMSC-induced NF-B activity was associated with bortezomib-resistant survival in RPMI8226 cells (34, 35) . Thus, we investigated whether HAPLN1 could cause bortezomib resistance in these cells. Bortezomib is cytotoxic (ϳ90%) in RPMI8226 cells at 10 nM over 3 days (Fig. 7F ). H1-P1 alone did not affect cell viability, but when combined with bortezomib, it induced bortezomib-resistant viability to ϳ80% (Fig. 7F ). Additional MM cell lines (H929, KMS11, and MM.1S) were also protected from bortezomib-induced toxicity (Fig. 7F ). Next, we analyzed primary CD138-positive MM cells from patient bone marrow aspirates. We observed H1-P1mediated protection from bortezomib-induced toxicity in three of four samples analyzed ( Fig. 7G ). Of the four patients analyzed, patients a, b, and d had received bortezomib treatment before biopsy, whereas patient c was newly diagnosed with MM and therefore had not received any prior treatment. Overall, our results demonstrate that HAPLN1-matrikine is detectable in MM patient BM microenvironment, and its HAPLN1-PTR1 domain is sufficient to induce resistance to bortezomib-induced cell death in MM cells.
Discussion
In the present study, we identified HAPLN1 as a BMSC-secreted factor that is capable of inducing an atypical, PIR NF-B signaling pathway and bortezomib-resistant survival in MM cells. To our knowledge, HAPLN1 has not been previously implicated in NF-B signaling or MM pathogenesis. Our study also suggests the possibility that HAPLN1-mediated NF-B activity might account for some of the chronic NF-B activation in MM cells that remains unexplained by genome-sequencing studies (5-7, 31, 33) . Full-length HAPLN1 lacked NF-B signaling activity; only the MMP-processed version, HAPLN1(32-354) (46) , and internal PTR domains had strong NF-B signaling activities (46) . ECM components that make up the tissue stroma can be proteolytically processed to produce soluble peptides and products, generally referred to as "matrikines," that can then signal to different cell types to change their phenotype (4, 44, 53, 54) . HAPLN1 is produced by cells in the TME, and that production could be enhanced during disease progression, particularly in patients with progres- 
Summary of H1-P1 induction of NF-B activity in different cell lines of different cell types
Cells were treated with 100 nM H1-P1 for 4 h as analyzed by EMSA. ϩ, a positive induction of NF-B activity; Ϫ, no induction of NF-B activity; ϩ/Ϫ, a very weak induction of NF-B activity. MM, multiple myeloma; MCL, mantle cell lymphoma; AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia.
Cell line
Cell type H1-P1 
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sive disease. We detected HAPLN1 fragments in a considerable fraction of MM patient BM plasma. Thus, it seems plausible that HAPLN1 is produced by BMSCs, and a proteolytic mechanism is associated with the release of NF-B-activating fragments, matrikines, to confer bortezomib resistance ( Fig. 8) .
Given the lack of detection of smaller PTR1/2 species in BMSC CMs, it seems plausible that MM cells themselves or other cell types could be involved in further processing of HAPLN1 into smaller matrikine fragments in MM patient bone marrow. The development of methodologies to accurately quantify HAPLN1-matrikine levels in individual MM patients could serve as a new biomarker for MM therapy and drug resistance. It is well-established that two major pathways of NF-B signaling, canonical and noncanonical, share the requirement for the ubiquitin-dependent proteasome pathway to inactivate inhibitor proteins (28, 30). Thus, NF-B activities present in the tumor cells are generally considered to be sensitive to inhibition by proteasome inhibitors, including bortezomib. However, our laboratory previously reported a case in which a considerable number of freshly isolated MM cells harbor NF-B activity that is highly resistant to bortezomib (34) . We also described an atypical NF-B activation mechanism, termed the PIR pathway, which is constitutively active in certain B lymphoma cell lines and highly resistant to inhibition by over 10 different types of proteasome inhibitors (37, 38) . This PIR NF-B activation involves selective degradation of IB␣, but not IB␤, in a manner highly resistant to proteasome inhibitors but is sensitive to inhibition by IKK inhibitors (38) . No extracellular ligand capable of inducing the PIR NF-B signaling pathway was previously known, but our current data demonstrate that HAPLN1 satisfies all of the expected features of such a PIR signaling ligand. HAPLN1 does not modify bortezomib's efficacy to block proteasome activity in MM cells; thus, IB␣ degradation occurs despite efficient inhibition of the proteasome activity. Moreover, MLN4924, an NEDD8-activating enzyme inhibitor, could block HAPLN1-induced IB␣ degradation and NF-B activation. Thus, further studies are required to determine how HAPLN1 induces PIR NF-B signaling (e.g. a cell surface receptor and other signaling components that make this pathway highly resistant to bortezomib inhibition). Our study suggests that HA binding is not required for NF-B signaling, thus tentatively ruling out the HA receptors as necessary mediators (47, 48) .
Beyond the currently discovered role in multiple myeloma disease, HAPLN1 is also expressed in other tissues, including the brain, heart, and digestive tract, and its overexpression has been linked to several human malignancies, including colorectal cancer, breast cancer, and hepatocellular carcinoma (55-57). Our limited analysis of different cell lines demonstrated 
that NF-B activation by H1-P1 is not limited to MM cell type but also detected in certain other cancer types. NF-B is wellknown to control inflammatory cytokine production as well as inducing cell survival mediators; therefore, HAPLN1-induced NF-B signaling could explain some of these HAPLN1-associated pathological processes. The newly uncovered role for HAPLN1 in NF-B signaling and possible other pathways opens future investigations to greatly deepen our understanding of this ECM protein's role in a multitude of physiological and pathological processes.
Experimental procedures
Antibodies and reagents
Antibodies against cMYC (9E10), HAPLN1 (H-93, K-14, C-14), IB␣ (C-21), IB␤ (C-20), IKK␣/␤ (H-470), cRel (C), p65 (C-20), p100/p52 (C-5), p50 (NLS), and RelB (C-19) were obtained from Santa Cruz Biotechnology. Other antibodies were against HAPLN1 (HPA019482, Sigma-Aldrich), phospho-IKK␣/␤ (2697, Cell Signaling Technology), phospho-IB␣ (9246, Cell Signaling Technology), and tubulin (CP06, Calbiochem). Reagents purchased include recombinant human TNF␣ (654205, EMD Millipore), lipopolysaccharide (L2880, Sigma-Aldrich), clasto-lactacystin ␤-lactone (154226-60-5, Sigma-Aldrich), bortezomib (S1013, Selleckchem), IKK16 (S2882, Selleckchem), MLN4924 (505477, Calbiochem), cycloheximide (C7698, Sigma-Aldrich), recombinant HAPLN1 (2608-HP, R&D Systems), low/high molecular weight hyaluronan (GLR001 and GLR004, R&D Systems), hyaluronidase (75790-208, ProSci), and GelCode TM Blue Stain (Thermo Fisher Scientific).
Cell line culture
RPMI8226, MM.1S, NCI-H929, and HEK293 cell lines were obtained from American Type Culture Collection (ATCC). Results are representative of at least three independent experiments. D, RPMI8226 cells pretreated for 30 min with 10 M IKK16 and 20 g/ml cycloheximide were stimulated with H1-P1 for the indicated times and analyzed by EMSA and immunoblotted (IB) for indicated proteins. Results are representative of three independent experiments. E, EMSA and immunoblot analysis for the indicated proteins of RPMI8226 cells pretreated for 30 min with increasing concentrations MLN4924 (M) and stimulated with 100 nM H1-P1 for 4 h or 10 ng/ml TNF␣ for 15 min and analyzed by EMSA and immunoblotting for the indicated proteins. F, results represent mean Ϯ S.D. (*, p Ͻ 0.05; **, p Ͻ 0.01) of quantification of three independent EMSA and phospho-IB␣ immunoblot analyses as in E at 100 M MLN29424. KMS11 and L363 cell lines were obtained from Dr. Lixin Rui. All multiple-myeloma cell lines were cultured at 37°C/5% CO 2 in RPMI1640 containing 10% FBS, 2% GlutaMAX (Gibco) ϩ 1% penicillin/streptomycin.
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Patient sample collection and processing
In accordance with the University of Wisconsin-Madison Institutional Review Board requirements (HO07403), human bone marrow aspirates (2-10 ml) were obtained with informed 
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consent from multiple myeloma patients at the University of Wisconsin Hospital and Clinics. The samples collected were only accompanied by diagnosis with no further information regarding patient history at the time of analysis. Some aspirates were spun at 400 ϫ g for 5 min at room temperature, and BM plasma fraction was removed and stored at Ϫ80°C for further analysis. Myeloma plasma cells were positively sorted with CD138ϩ magnetic MACS beads (Miltenyi Biotec) to Ͼ90% purity as described previously (34) . CD138-negative fractions were cultured in "BMSC medium" (OptiMEM containing 10% FBS, 2% GlutaMAX ϩ 1ϫ NEAA (Gibco), and 1% penicillin/ streptomycin) at 37°C in a 5% CO 2 incubator, and BMSCs were derived by removal of nonadherent cells 24 h after plating. Adherent cells were then expanded until passage 3-4 and cryopreserved as described previously (58) .
Conditioned medium mass spectrometry analysis
Partial enrichment of H1-ESC-MSCs-induced factor was described previously (35) . Fractions were analyzed by SDS-PAGE and stained with Coomassie Blue. Unique bands were cut, and the protein identification was carried out at ProtTech, Inc. by using nano-LC-MS/MS peptide-sequencing technology. In brief, each protein gel band was destained, cleaned, and digested in-gel with sequencing grade modified trypsin. The resulting peptide mixture was analyzed by a LC-MS/MS system, in which a high-pressure liquid chromatograph with a 75-m inner diameter reverse phase C18 column was online-coupled with an ion trap mass spectrometer. The mass spectrometric data acquired were used to search the most recent non-redundant protein database with ProtTech's proprietary software suite.
HEK293 transient transfection and conditioned media
Multiple myeloma BMSCs were used to isolate total RNAs, and cDNAs encoding each of the mass spectrometry hits in full length were PCR-amplified with the following primers: G3BP, forward (5Ј-acgaagcttcatgacccctccgaggctcttc-3Ј) and reverse (5Ј-agtggatccgtgtccacacctgaggagttgg-3Ј); calumenin, forward (5Ј-gtggaattcctatggacctgcgacagtttctt-3Ј) and reverse (5Ј-ctcctcgcgtgaactcatcatgccgta-3Ј); osteonectin, forward (5Ј-attctgcagaatgagggcctggatcttctttctcc-3Ј) and reverse (5Ј-ctctcgagtgatcacaagatccttgtcgatatc-3Ј); HAPLN1, forward (5Ј-cgcggatccaatgaagagtctactt-3Ј) and reverse (5Ј-gcgactcgaggttgtatgctctgaa-3Ј). Then they were inserted into a pSecTag2A plasmid and sequence-verified for integrity. pSecTag2A adds a C-terminal Myc tag and His 6 tag for detection of secreted factors. HEK293 cells were transiently transfected via a standard calcium phosphate precipitation protocol with each plasmid. CM was collected at 72 h after transfection. Expression and secretion of each of the transfected factors was analyzed by immunoblot using anti-Myc antibody.
CM analysis
CM was prepared by culturing a confluent monolayer of BMSCs, washing monolayer three times with 1ϫ PBS and culturing the cells in serum-free BMSC medium at 37°C. After 48 -72 h, the CM was removed and centrifuged at 3,000 rpm for 5 min to remove cellular debris. Then 0.5 ml of CM was TCAprecipitated and analyzed by SDS-PAGE and immunoblotting.
EMSAs
EMSAs to measure NF-B activity in myeloma cell lines were performed as described previously (36) using 32 P-labeled double-stranded DNA probes with the following sequences: B, 5Ј-tcaacagagggactccgagaggcc-3Ј; Oct-1, 5Ј-tgtcgaatgcaaatcactagaa-3Ј. Briefly, cell extracts were made using TOTEX buffer, as described previously (38) , and 10 g of extracts were separated on 4% native polyacrylamide gel, dried, and exposed to a phosphor screen (Amersham Biosciences), followed by quantitation of NF-B DNA binding through ImageQuant software (GE Healthcare). Each NF-B lane was normalized to Oct-1 values from the same sample and then to the vehicle-treated control values for each experiment to derive -fold induction.
SDS-PAGE and immunoblot analysis
Myeloma cell lines were pelleted and lysed in TOTEX buffer, as described previously (38) . Equal amounts (100 g) of soluble protein were run on denaturing 10 -12.5% SDS-polyacrylamide gel and transferred onto a polyvinylidene fluoride or nitrocellulose membrane (GE Healthcare). The membrane was then incubated with the appropriate antibodies as described previously (36) . Immunoblots were analyzed by enhanced chemiluminescence as described by the manufacturer (GE Healthcare). Quantification of immunoblots was performed using ImageJ (National Institutes of Health) to calculate the signal intensity of protein(s) of interest normalized to total protein loading (tubulin or actin) for each lane from the same sample and then to vehicle control values for each experiment.
Purification and expression of GST-tagged proteins
HAPLN1 domains (IG, PTR1, and PTR2) were PCR-amplified with the following primers: IG, forward (5Ј-cacacaggatccgatcatctttcagac-3Ј) and reverse (5Ј-gccgctcgagaagtccagtgctaccac-3Ј); PTR1, forward (5Ј-gcgggatccgtggtattcccttac-3Ј) and reverse (5Ј-gccgctcgagattgaaattggatgtaa-3Ј); PTR2, forward (5Ј-cgcggatccggccgtttttactatc-3Ј) and reverse (5Ј-gccgctcgaggttgtatgctctgaag-3Ј). Double-stranded oligonucleotides encoding HAPLN1(32-354) or H1-P1 HABD mt mutant were purchased from Integrated DNA Technologies and inserted into pGEX6p-1 plasmid and sequence-verified for integrity. Plasmids were transformed into the BL21 Rosetta 2 E. coli strain and induced with 1 mM isopropyl 1-thio-␤-D-galactopyranoside, followed by lysis and purification by glutathione-agarose beads (G4510, Pierce) and elution by 50 mM reduced glutathione at pH 8.0. Removal of GST from GST-H1-P1 to generate H1-P1c was done by incubation with GST-fused PreScission protease (GE Healthcare) as described previously (59) .
Endotoxin quantification
Endotoxin levels were assessed using the Pierce LAL chromogenic endotoxin quantification kit (88282, Thermo Fisher Scientific). Quantification was performed in 96-well tissue culture grade plates and assayed per the manufacturer's instructions.
HAPLN1-mediated NF-B activity and drug resistance in myeloma 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay
MTT (M6494) was purchased from Thermo Fisher Scientific. 10 4 to 10 5 cells/well were plated in triplicate in a 96-well clear bottom microassay plate and assayed per the manufacturer's instructions. Cells containing formazan (MTT) were dissolved in 50 -75 l of DMSO, and formazan concentration was measured by absorbance at 540 nm. The assays were run in three biological replicates. The data were normalized to the mean of untreated control.
26S proteasome activity assay
Cells (20,000/well) were plated in a white 96-well microassay plate and treated with varying concentrations of bortezomib in the absence or presence of 100 nM H1-P1 for 4 h. Proteasome activity was assayed using a cell-based Proteasome-Glo assay (G8660, Promega Corp.) according to the manufacturer's instructions, and luminescence was recorded on a luminometer (PerkinElmer Life Sciences). Following subtraction of background, relative light units for the no-drug control indicate 100% proteasome activity, and the ratio of relative light units for each dose of bortezomib over control was used to determine relative chymotryptic activity.
qRT-PCR analysis
Total RNAs from treated cells were purified by a Nucleospin RNA II column (740955, Clontech) according to the manufacturer's instructions. cDNAs were synthesized from the total RNAs using iScript cDNA synthesis kit (1708891, Bio-Rad). qRT-PCR was performed and analyzed using a Bio-Rad CFX Connect real-time system. Relative expression was determined by ⌬⌬Ct calculation and normalized to GAPDH mRNA levels of the same sample. The qRT-PCR primer sequences were as follows: HAPLN1, forward (5Ј-gatactgttgtggtagcactgg-3Ј) and reverse (5Ј-tgctgcgcctcgtgaaaattgag-3Ј); GAPDH, forward (5Јgaaggtcggagtcaacggattt-3Ј) and reverse (5Ј-gaatttgccatgggtggaat-3Ј).
Bone marrow plasma analysis
Plasma layer from bone marrow aspirates (20 l) was added to 980 l of 1ϫ PBS. 200 l of Affi-Gel Blue gel beads (1537301, Bio-Rad) (1:1 slurry in 1ϫ PBS) were added and tumbled at 4°C for 2-3 h. Samples were then centrifuged at 3,000 rpm for 5 min, and supernatant was subjected to a second depletion with 100 l of Affi-Gel Blue beads (3:1 bead slurry in 1ϫ PBS) overnight at 4°C to remove albumin. 100 l of protein G-Sepharose 4 Fast Flow (17-0618-01, GE Healthcare) (1:1 slurry in 1ϫ PBS) was added to supernatant and tumbled for 2-3 h at 4°C. Following centrifugation, supernatant was incubated with 100 l of protein A Sepharose Cl-4B (17-0963-03, GE Healthcare) (1:1 slurry in 1ϫ PBS) for an additional 2-3 h to remove antibodies. Final supernatant was TCA-precipitated and analyzed by SDS-PAGE and immunoblotting using different HAPLN1 antibodies. To avoid carryover signals, TCA-precipitated supernatant was split into two equal samples, and two SDS-polyacrylamide gels were run in parallel and probed with different antibodies (one membrane probed with K-14 and H-93 and the second membrane probed with C-14 and HPA019482).
Statistical analysis
An unpaired two-sided Student's t test was used to compare two independent groups. Two-way analysis of variance with multiple-comparison test was used to compare bortezomib inhibition and IB degradation curves. For comparison of HAPLN1 detection and progressive disease, a two-tailed Wilcox-Mann-Whitney test was used. A p value of Ͻ0.05 was considered statistically significant. Analysis was performed with GraphPad Prism Software (GraphPad Software Inc.).
